# US 2023/0272045 A1 · Il-1 receptor antagonist (il-1 ra) fusion proteins binding to the extracellular matrix

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0272045 A1
- Document ID: US20230272045A1
- Status: Published application
- Kind: A1
- Application number: 18/001,480
- Filed: 2021-06-11
- Published: 2023-08-31
- Earliest claimed: 2020-06-12
- Assignees: Monash University
- Applicants: Monash University
- Inventors: Mikaël MARTINO; Ziad JULIER
- Web page: https://patentgrep.com/patent/US20230272045A1

## CPC

- C07K 14/54: Interleukins [IL]
- C07K 14/7155: {for interleukins [IL]}
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- C07K 14/475: Growth factors; Growth regulators
- C07K 14/485: Epidermal growth factor [EGF], i.e. urogastrone
- C07K 14/515: Angiogenesic factors; Angiogenin
- C07K 14/52: Cytokines; Lymphokines; Interferons
- C07K 14/71: for growth factors; for growth regulators
- C12N 15/62: DNA sequences coding for fusion proteins
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 2319/33: fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
- C07K 2319/70: containing domain for protein-protein interaction
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention provides a fusion protein comprising interleukin-1 receptor antagonist (IL-1Ra) and an extracellular matrix (ECM) binding peptide which specifically binds to one or more or all extracellular matrix proteins selected from the group consisting of fibrinogen, fibronectin, vitronectin, tenascin C and heparan sulfate and use of the fusion protein to treat conditions in which administration of IL-1Ra is beneficial or in which IL-1R1 signalling needs to be dampened, to enhance tissue regeneration, particularly bone regeneration and/or wound repair or for treating wounds, burns and muscle, cartilage, tendon and bone disorders, to enhance the regenerative activity of growth factor administration or to reduce inflammation or desensitisation of a cell to growth factor stimulation.

## Claims

### Claim 1

A fusion protein comprising interleukin-1 receptor antagonist (IL-1Ra) and an extracellular matrix (ECM) binding peptide which specifically binds to one or more or all extracellular matrix proteins selected from the group consisting of fibrinogen, fibronectin, vitronectin, tenascin C and heparan sulfate.

### Claim 2 (depends on 1)

The fusion protein of claim 1 in which the ECM binding peptide comprises a heparin binding domain of placental growth factor comprising the amino acid sequence provided as SEQ ID NO: 1 (RRRPKGRGKRRREKQRPTD) or conservative variants thereof.

### Claim 3 (depends on 1)

The fusion protein of claim 1 in which the ECM binding peptide comprises a peptide from amphiregulin (AREG) comprising the amino acid sequence provided as SEQ ID NO: 2 (RKKKGGKNGKNRR) or conservative variations thereof.

### Claim 4 (depends on 1)

The fusion protein of claim 1 in which the ECM binding peptide comprises a peptide from neurturin (NRTN) comprising the amino acid sequence provided as SEQ ID NO: 3 (RRLRQRRRLRRE) or conservative variations thereof.

### Claim 5 (depends on 1)

The fusion protein of claim 1 comprising the ECM binding peptide linked at its N terminus to IL-1Ra either directly or indirectly via a linker.

### Claim 6 (depends on 1)

The fusion protein of claim 1 in which the IL-1Ra amino acid sequence is SEQ ID NO:4 or SEQ ID NO: 5.

### Claim 7 (depends on 1)

The fusion protein of claim 1 in which the ECM binding peptide has or comprises the amino acid sequence provided as any one of SEQ ID NO: 1-3 or 8-59.

### Claim 8 (depends on 1)

The fusion protein of claim 1 having the amino acid sequence of SEQ ID NO: 60 or SEQ ID NO: 61.

### Claim 9 (depends on 1)

A nucleic acid molecule encoding the fusion protein of claim 1 or a vector comprising a nucleic acid molecule encoding the fusion protein of claim 1 or a cell or a non human organism transformed or transfected with a nucleic acid molecule encoding the fusion protein of claim 1 or with a vector comprising a nucleic acid molecule encoding the fusion protein of claim 1.

### Claim 10 (depends on 1)

A method of
(a) treating a condition in which IL-1Ra administration is beneficial or in which IL-1R1 signalling needs to be dampened,
(b) enhancing tissue regeneration, particularly bone regeneration and/or wound repair or for treating wounds, burns and muscle, cartilage, tendon and bone disorders,
(c) enhancing the regenerative activity of growth factor administration, or
(d) reducing inflammation or desensitisation of a cell to growth factor stimulation in a subject being administered a growth factor,
the method comprising administering to a subject in need thereof the fusion protein of claim 1, a nucleic acid molecule encoding the fusion protein of claim 1, or a vector comprising a nucleic acid molecule encoding the fusion protein of claim 1.

### Claim 11 (depends on 10)

The method of claim 10 in which the condition in which IL-1Ra administration is beneficial or in which IL-1R1 signalling needs to be dampened is a condition requiring tissue regeneration, particularly bone regeneration and/or wound repair.

### Claim 12 (depends on 10)

The method of claim 10 in which the condition in which IL-1Ra administration is beneficial or in which IL-1R1 signalling needs to be dampened is a wound, burn or muscle condition or injury or a cartilage, tendon or bone disorder or injury, particularly a diabetic wound.
